AR
Data & Repro
armored-cart-design-agent
Design armored CAR-T cells with cytokine payloads and resistance mechanisms.
FreedomIntelligence/OpenClaw-Medical-SkillsView
Data & Repro
TO
tooluniverse-gwas-drug-discovery
Maintainer FreedomIntelligence · Last updated April 1, 2026
This skill bridges genetic discoveries from GWAS with drug development by: 1. **Identifying genetic risk factors** - Finding genes associated with diseases 2. **Assessing druggability** - Evaluating which genes can be targeted by drugs 3. **Prioriti.
Original source
FreedomIntelligence/OpenClaw-Medical-Skills
https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/tooluniverse-gwas-drug-discovery
- Maintainer
- FreedomIntelligence
- License
- MIT
- Last updated
- April 1, 2026
Skill Snapshot
Key Details From SKILL.md
Key Notes
- Transform genome-wide association studies (GWAS) into actionable drug targets and repurposing opportunities.
- This skill bridges genetic discoveries from GWAS with drug development by:.
- 1. Identifying genetic risk factors - Finding genes associated with diseases 2. Assessing druggability - Evaluating which genes can be targeted by drugs 3. Prioritizing targets - Ranking candidates by genetic evidence strength 4. Finding existing drugs - Discovering approved/investigational compounds 5. Identifying repurposing opportunities - Matching drugs to new indications.
Source Doc
Excerpt From SKILL.md
Why This Matters
From Genetics to Therapeutics: GWAS has identified thousands of disease-associated variants, but most haven't been translated into therapies. This skill accelerates that translation.
Success Stories:
- PCSK9 (cholesterol) → Alirocumab, Evolocumab (approved 2015)
- IL-6R (rheumatoid arthritis) → Tocilizumab (approved 2010)
- CTLA4 (autoimmunity) → Abatacept (approved 2005)
- CFTR (cystic fibrosis) → Ivacaftor (approved 2012)
Genetic Evidence Doubles Success Rate: Targets with genetic support have 2x higher probability of clinical approval (Nelson et al., Nature Genetics 2015).
1. GWAS Evidence Strength
Not all genetic associations are equal. Consider:
- P-value - Statistical significance (genome-wide: p < 5×10⁻⁸)
- Effect size (beta/OR) - Magnitude of genetic effect
- Replication - Confirmed in multiple studies
- Sample size - Larger studies = more reliable
- Population diversity - Validated across ancestries
2. Druggability Criteria
A good drug target must be:
- Accessible - Protein location allows drug binding (extracellular > intracellular)
- Modality match - Target class fits drug type (GPCR → small molecule, receptor → antibody)
- Tractable - Binding pocket suitable for drug design
- Safe - Minimal off-target effects, not essential in all tissues
Use cases
- Use when discovering drug targets from GWAS data, finding drug repurposing opportunities from genetic associations, or translating GWAS findings into therapeutic leads.
Not for
- Do not rely on this catalog entry alone for installation or maintenance details.
Related skills
Related skills
AR
Data & Repro
arxiv-search
Search arXiv physics, math, and computer science preprints using natural language queries. Powered by Valyu semantic search.
FreedomIntelligence/OpenClaw-Medical-SkillsView
AU
Data & Repro
autonomous-oncology-agent
Autonomous oncology research agent: literature mining, trial matching, biomarker analysis, and treatment hypothesis generation.
FreedomIntelligence/OpenClaw-Medical-SkillsView
BI
Data & Repro
bio-cfdna-preprocessing
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-aware duplicate remo…
FreedomIntelligence/OpenClaw-Medical-SkillsView